A Translational Perspective – Biacore Systems in Discovery and Early-Stage Development
Translational science has launched a new era of antibody therapeutics, driving demand for novel antibody formats designed to improve the efficacy of therapies and reach new targets. For a smooth molecule journey from benchtop to clinic you need to make the most informed candidate selection and reduce the risk of failure and complications during development.
Cytiva's BiacoreTM systems support informed decision-making during the lead candidate selection process. Its technology delivers valuable insights into developability such as manufacturability and safety.
Download this whitepaper to learn how surface plasmon resonance (SPR) can:
• Enhance the drug discovery process for translational scientists
• Support informed decision making during the lead candidate selection process
• Reduce the risk of failure and complications during development
• Leverage technology to deliver valuable insights into developability — for a smooth journey from benchtop to clinic